FDA Clears Monthly Subcutaneous Olanzapine Injectable for Schizophrenia
The FDA has approved Weltruza, a once-monthly subcutaneous long-acting injectable form of olanzapine, for schizophrenia. Phase 3 SOLARIS data supported the approval, and the product does not require loading doses, oral supplementation, or monitoring after injection.
The FDA has approved Weltruza for schizophrenia. It is a long-acting injectable form of olanzapine administered once a month beneath the skin. The summary states that Phase 3 SOLARIS data backed the clearance. It also says the product avoids dose-loading steps, additional oral medicine, and post-dose observation.
The approval adds a monthly subcutaneous option in this treatment area. The available material does not include further clinical details, so the story centers on the regulatory decision and the trial cited as support.
For people living with schizophrenia and their caregivers, a monthly subcutaneous option that the summary says avoids dose-loading, oral medicine, and post-dose observation could simplify some treatment routines and may support adherence. Clinicians may gain another long-acting choice to discuss, though actual uptake and outcomes would depend on access, cost, patient preference, and clinical judgment. The approval's broader impact may be modest until real-world experience accumulates.